---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016846"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:53:45.159301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kezar Q2 2022: Net loss $16.2M, cash $306.8M; positive Phase 2 lupus nephritis data

## Summary
- Positive MISSION Phase 2 topline: 64.7% ORR, 35.2% CRR in lupus nephritis patients.
- Cash, cash equivalents and marketable securities totaled $306.8M as of June 30, 2022 (up from $208.4M year-end 2021).
- Net loss for Q2 2022 was $16.2M ($0.25 per share) vs $13.0M in Q2 2021.
- Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer in July 2022.
- R&D expenses $11.3M (+$2.0M YoY); G&A $5.0M (+$1.3M YoY).

## SEC filing metadata
- accession: 0000950170-22-016846
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/0000950170-22-016846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017022016846/kzr-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016846
- JSON: https://secwatch.observer/filing/0000950170-22-016846.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.